A-10 DRUGS USE IN DIABETES

3PC-032

28[™] EAHP CONGRESS 20-21-22 MARCH 2024

Sustainable healthcare -**Opportunities & strategies**

OPTIMIZATION OF AN INSULIN 1 IU/ML EYE DROP FORMULATION FOR THE TREATMENT OF CORNEAL ULCERS

¹Prieto Román, S., ¹López Guerra, L., ¹Izquierdo García, E., ¹Cabello Cuevas M.C., ¹López Morales, S., ¹Garrido Dorao, A., ¹Monje Montoya, P., ²Talaván Zanón, T., ¹Escobar Rodríguez, I. ¹Infanta Leonor University Hospital, Pharmacy Department, Madrid, Spain. ²Infanta Leonor University Hospital, Clinical Analysis Department, Madrid, Spain.





AIM AND OBJECTIVES

Optimize and study the stability through galenic validation of 1 IU/mL insulin eye drops formulated using normal saline in sterile

amber glass dropper bottles and in low density polyethylene (LDPE) dropper bottles.

MATERIALS AND METHODS

All samples were prepared in a horizontal laminar-flow cabinet following the Good Practice Guidelines for sterile drug preparation

Eye drop	Composition per 5 mL	Storage conditions	Packaged
IN1	Insulina regular 100 UI/mL vial (Actrapid®) 0,05 ml Cloruro sódico 0,9%c.s.p 5 ml	Refrigeration 2-8°C	Sterile ambar glass dropper bottles
IN2			Sterile low density polyethylene (LDPE) dropper bottles

RESULTS



30-day galenic validation:
Clarity
Osmolality ✓ Colour ✓ Sterility Days 0,1,2,7,15,22,30 ✓ pH

property

Units per sampling NOTE: pH value at which insulin point and analyzed commercial presentations are buffered 6.9-7.8; pH value of normal saline 6.0.





The formulation **IN1** was **rejected**.

Tested property	Outcome Days 0,1,2,7,15,22,30		
Clarity	Transparent and homogeneus. Absence of particulates.		
Colour	Uncolored		
рH	6-6,3		
Osmolality	282-286 mOsm/kg		
Sterility	Absence of microbiological growth		

All samples maintained the characteristics described during the 30 days of galenic validation.

CONCLUSION AND RELEVANCE

The 1 IU/mL insulin eye drops packaged in LPDE dropper bottles showed no changes in the parameters studied throughout the 30-day galenic validation. They also remained within the eye pH range of maximum tolerability (3.5–10.5). It is required more physicochemical and microbiological stability studies to confirm the stability of the formulation.



28th Congress of the EAHP, 20-22 March, 2024 – Bordeaux, France Contact us: sprietor@salud.madrid.org Hospital Universitario Infanta Leonor, Madrid, Spain

